Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Effisayil 1:Multi-center, Double-blind, Randomised, Placebo-controlled, Phase II Study to Evaluate Efficacy, Safety and Tolerability of a Single Intravenous Dose of Spesolimab (BI 655130) in Patients With Generalized Pustular Psoriasis (GPP) Presenting With an Acute Flare of Moderate to Severe Intensity

Next Previous
Trial Profile

Effisayil 1:Multi-center, Double-blind, Randomised, Placebo-controlled, Phase II Study to Evaluate Efficacy, Safety and Tolerability of a Single Intravenous Dose of Spesolimab (BI 655130) in Patients With Generalized Pustular Psoriasis (GPP) Presenting With an Acute Flare of Moderate to Severe Intensity

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 18 Mar 2025

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Spesolimab (Primary)
  • Indications Generalised pustular psoriasis
  • Focus Registrational; Therapeutic Use
  • Acronyms Effisayil 1; Effisayil TM 1
  • Sponsors Boehringer Ingelheim

Most Recent Events

  • 01 Mar 2025 Results of histologic, transcriptomic, and proteomic analyses of lesional and nonlesional skin and whole-blood samples, published in the Journal of Investigative Dermatology.
  • 16 Oct 2023 Subgroup analysis results published in the Dermatology and Therapy.
  • 01 Aug 2023 Results assessing efficacy of pre-specified subgroup analysis spesolimab for the treatment of generalized pustular psoriasis flares across pre-specified patient subgroups in the Effisayil 1 study published in the Experimental Dermatology

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top